Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Carcinoma, Non-Small-Cell Lung × Acetaminophen × Clear all

Phase

Phase NA 1 Phase 3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pain 4 Neoplasms 2 Multiple Myeloma 2 Cancer Pain 2 Squamous Cell Carcinoma of Head and Neck 1 Pain, Postoperative 1 Paget Disease, Extramammary 1 Ovarian Neoplasms 1 Lymphoma 1 Head and Neck Neoplasms 1 Fallopian Tube Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 162 Cisplatin 133 Pemetrexed 125 Paclitaxel 108 Docetaxel 92 pembrolizumab 75 Gemcitabine 57 Erlotinib Hydrochloride 42 Radiotherapy 35 durvalumab 29 Gefitinib 29 Vinorelbine 26 Bevacizumab 24 Nivolumab 22 Drug Therapy 21 atezolizumab 18 130-nm albumin-bound paclitaxel 16 osimertinib 15 tislelizumab 14 Radiosurgery 13 Crizotinib 13 Etoposide 12 Afatinib 10 aumolertinib 9 Surgical Procedures, Operative 9 Albumin-Bound Paclitaxel 9 icotinib 8 Specimen Handling 8 Observation 8 Ipilimumab 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06305754 2026-03-13

MK-2870-009

Merck Sharp & Dohme LLC

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡